Direct to confusion: lessons learned from marketing BRCA testing
American Journal of Bioethics 2008 June; 8(6): 5-8
Myriad Genetics holds a patent on testing for the hereditary breast and ovarian cancer genes, BRCA1 and BRCA2, and therefore has a forced monopoly on this critical genetic test. Myriad launched a Direct-to-Consumer (DTC) marketing campaign in the Northeast United States in September 2007 and plans to expand that campaign to Florida and Texas in 2008. The ethics of Myriad's patent, forced monopoly and DTC campaign will be reviewed, as well as the impact of this situation on patient access and care, physician liability, and the future of DTC campaigns for genetic testing.
Permanent LinkFind Full Text at Georgetown University Library
Full Text from Publisher
Showing items related by title, author, creator and subject.
Direct-to-consumer marketing of BRCA testing: assessing the short term impact on individuals at risk and the practice of cancer genetic testing Gilson Slate, N.; Friedman, S.; Schwartz, R.; Hiller, E.; Rosen-Sheidley, B. (2008-12)
Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey Di Prospero, Lisa S.; Seminsky, Maureen; Honeyford, Joanne; Doan, Brian; Franssen, Edmee; Meschino, Wendy; Chart, Pamela; Warner, Ellen (2001-04-03)